Is Corcept Therapeutics Incorporated (CORT) a Good Choice in Biotechnology Tuesday? – InvestorsObserver

Corcept Therapeutics Incorporated (CORT) is near the middle in its industry group according to InvestorsObserver. CORT gets an overall rating of 37. That means it scores higher than 37 percent of stocks. Corcept Therapeutics Incorporated gets a 50 rank in the Biotechnology industry. Biotechnology is number 110 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Corcept Therapeutics Incorporated (CORT) stock is trading at $21.51 as of 10:00 AM on Tuesday, Jun 22, a decline of -$1.47, or -6.4% from the previous closing price of $22.98. The stock has traded between $21.11 and $21.76 so far today. Volume today is light. So far 151,745 shares have traded compared to average volume of 632,416 shares.

Click Here to get the full Stock Score Report on Corcept Therapeutics Incorporated (CORT) Stock.

Visit link:
Is Corcept Therapeutics Incorporated (CORT) a Good Choice in Biotechnology Tuesday? - InvestorsObserver

Is Citius Pharmaceuticals Inc (CTXR) Stock at the Top of the Biotechnology Industry? – InvestorsObserver

The 83 rating InvestorsObserver gives to Citius Pharmaceuticals Inc (CTXR) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 100 percent of stocks in the Biotechnology industry, CTXRs 83 overall rating means the stock scores better than 83 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 83 would rank higher than 83 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Citius Pharmaceuticals Inc (CTXR) stock is trading at $4.15 as of 1:22 PM on Monday, Jun 21, a gain of $0.46, or 12.47% from the previous closing price of $3.69. The stock has traded between $3.73 and $4.35 so far today. Volume today is above average. So far 17,600,254 shares have traded compared to average volume of 7,872,818 shares.

Click Here to get the full Stock Score Report on Citius Pharmaceuticals Inc (CTXR) Stock.

Read more:
Is Citius Pharmaceuticals Inc (CTXR) Stock at the Top of the Biotechnology Industry? - InvestorsObserver

Is IntelGenx Technologies Corp. (IGXT) a Leader in the Biotechnology Industry? – InvestorsObserver

IntelGenx Technologies Corp. (IGXT) is around the top of the Biotechnology industry according to InvestorsObserver. IGXT received an overall rating of 58, which means that it scores higher than 58 percent of all stocks. IntelGenx Technologies Corp. also achieved a score of 91 in the Biotechnology industry, putting it above 91 percent of Biotechnology stocks. Biotechnology is ranked 107 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

IntelGenx Technologies Corp. (IGXT) stock is trading at $0.54 as of 9:39 AM on Monday, Jun 21, a drop of -$0.02, or -3.53% from the previous closing price of $0.55. The stock has traded between $0.53 and $0.58 so far today. Volume today is less active than usual. So far 81,071 shares have traded compared to average volume of 260,291 shares.

Click Here to get the full Stock Score Report on IntelGenx Technologies Corp. (IGXT) Stock.

See more here:
Is IntelGenx Technologies Corp. (IGXT) a Leader in the Biotechnology Industry? - InvestorsObserver

Should You Hold Regulus Therapeutics Inc (RGLS) in Biotechnology Industry? – InvestorsObserver

Regulus Therapeutics Inc (RGLS) is near the middle in its industry group according to InvestorsObserver. RGLS gets an overall rating of 40. That means it scores higher than 40 percent of stocks. Regulus Therapeutics Inc gets a 61 rank in the Biotechnology industry. Biotechnology is number 107 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Regulus Therapeutics Inc (RGLS) stock is trading at $0.95 as of 10:47 AM on Monday, Jun 21, an increase of $0.07, or 8.35% from the previous closing price of $0.88. The stock has traded between $0.90 and $0.98 so far today. Volume today is low. So far 2,781,969 shares have traded compared to average volume of 4,362,428 shares.

Click Here to get the full Stock Score Report on Regulus Therapeutics Inc (RGLS) Stock.

Read more here:
Should You Hold Regulus Therapeutics Inc (RGLS) in Biotechnology Industry? - InvestorsObserver

Is Aptevo Therapeutics Inc (APVO) a Good Choice in Biotechnology Monday? – InvestorsObserver

Aptevo Therapeutics Inc (APVO) is near the top in its industry group according to InvestorsObserver. APVO gets an overall rating of 59. That means it scores higher than 59 percent of stocks. Aptevo Therapeutics Inc gets a 92 rank in the Biotechnology industry. Biotechnology is number 107 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Aptevo Therapeutics Inc (APVO) stock is lower by -12.66% while the S&P 500 is higher by 0.56% as of 9:54 AM on Monday, Jun 21. APVO is lower by -$3.47 from the previous closing price of $27.36 on volume of 85,227 shares. Over the past year the S&P 500 is higher by 34.39% while APVO is higher by 305.77%. APVO lost -$7.67 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Aptevo Therapeutics Inc (APVO) Stock.

More:
Is Aptevo Therapeutics Inc (APVO) a Good Choice in Biotechnology Monday? - InvestorsObserver

Is PDS Biotechnology Corp (PDSB) the Top Pick in the Biotechnology Industry? – InvestorsObserver

PDS Biotechnology Corp (PDSB) is the highest overall rated company in the Biotechnology industry with an overall score of 91. PDSB is up 734.78% so far this year after the company closed yesterday at $11.52. The overall score measures the company's performance based-off both short and long term indicators and means that PDSB scores better than 91% of the overall market.

PDS Biotechnology Corp is a strong performer in the Biotechnology industry, which has an average overall score of 37. This means that, on average, the stocks in this industry score higher than 37% of the stock market.

To see InvestorsObserver's Sentiment Score for PDS Biotechnology Corp click here.

PDSB has been trading bullishly recently. The stock is trading down -10.42% this week following yesterday's decline. PDSB has an average analyst ranking of Strong Buy with an average price target of $19.25.

Click Here to get the full Stock Score Report on PDS Biotechnology Corp (PDSB) Stock.

See original here:
Is PDS Biotechnology Corp (PDSB) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Is Alnylam Pharmaceuticals, Inc. (ALNY) Stock at the Top of the Biotechnology Industry? – InvestorsObserver

Alnylam Pharmaceuticals, Inc. (ALNY) is around the top of the Biotechnology industry according to InvestorsObserver. ALNY received an overall rating of 42, which means that it scores higher than 42 percent of all stocks. Alnylam Pharmaceuticals, Inc. also achieved a score of 67 in the Biotechnology industry, putting it above 67 percent of Biotechnology stocks. Biotechnology is ranked 111 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 42 would rank higher than 42 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Alnylam Pharmaceuticals, Inc. (ALNY) stock has risen 0.71% while the S&P 500 has fallen -0.92% as of 11:42 AM on Friday, Jun 18. ALNY is up $1.23 from the previous closing price of $172.25 on volume of 308,707 shares. Over the past year the S&P 500 has gained 34.27% while ALNY is up 22.18%. ALNY lost -$7.55 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Alnylam Pharmaceuticals, Inc. (ALNY) Stock.

Visit link:
Is Alnylam Pharmaceuticals, Inc. (ALNY) Stock at the Top of the Biotechnology Industry? - InvestorsObserver

Is Prothena Corporation PLC (PRTA) a Good Buy in the Biotechnology Industry? – InvestorsObserver

Prothena Corporation PLC (PRTA) is around the top of the Biotechnology industry according to InvestorsObserver. PRTA received an overall rating of 58, which means that it scores higher than 58 percent of all stocks. Prothena Corporation PLC also achieved a score of 91 in the Biotechnology industry, putting it above 91 percent of Biotechnology stocks. Biotechnology is ranked 111 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Prothena Corporation PLC (PRTA) stock is up 7.31% while the S&P 500 is lower by -0.8% as of 9:52 AM on Friday, Jun 18. PRTA is up $3.56 from the previous closing price of $48.72 on volume of 92,233 shares. Over the past year the S&P 500 is up 34.43% while PRTA is up 409.06%. PRTA lost -$3.11 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Prothena Corporation PLC (PRTA) Stock.

Read more from the original source:
Is Prothena Corporation PLC (PRTA) a Good Buy in the Biotechnology Industry? - InvestorsObserver

Where Does Arcturus Therapeutics Holdings Inc (ARCT) Stock Fall in the Biotechnology Field After It Is Down -9.97% This Week? – InvestorsObserver

Arcturus Therapeutics Holdings Inc (ARCT) is around the top of the Biotechnology industry according to InvestorsObserver. ARCT received an overall rating of 50, which means that it scores higher than 50 percent of all stocks. Arcturus Therapeutics Holdings Inc also achieved a score of 82 in the Biotechnology industry, putting it above 82 percent of Biotechnology stocks. Biotechnology is ranked 107 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 50 would rank higher than 50 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Arcturus Therapeutics Holdings Inc (ARCT) stock is down -7.87% while the S&P 500 has gained 0.56% as of 9:53 AM on Monday, Jun 21. ARCT is down -$2.76 from the previous closing price of $35.09 on volume of 100,649 shares. Over the past year the S&P 500 is higher by 34.39% while ARCT is down -20.57%. ARCT lost -$4.86 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Arcturus Therapeutics Holdings Inc (ARCT) Stock.

Original post:
Where Does Arcturus Therapeutics Holdings Inc (ARCT) Stock Fall in the Biotechnology Field After It Is Down -9.97% This Week? - InvestorsObserver

Where Does Agenus Inc (AGEN) Stock Fall in the Biotechnology Field After It Is Higher By 7.21% This Week? – InvestorsObserver

The 48 rating InvestorsObserver gives to Agenus Inc (AGEN) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 81 percent of stocks in the Biotechnology industry, AGENs 48 overall rating means the stock scores better than 48 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 48 means the stock is more attractive than 48 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Agenus Inc (AGEN) stock is trading at $5.50 as of 10:41 AM on Thursday, Jun 17, an increase of $0.50, or 10% from the previous closing price of $5.00. The stock has traded between $5.14 and $5.66 so far today. Volume today is less active than usual. So far 3,061,829 shares have traded compared to average volume of 7,076,348 shares.

Click Here to get the full Stock Score Report on Agenus Inc (AGEN) Stock.

Link:
Where Does Agenus Inc (AGEN) Stock Fall in the Biotechnology Field After It Is Higher By 7.21% This Week? - InvestorsObserver

Is SAGE Therapeutics Inc (SAGE) Stock at the Top of the Biotechnology Industry? – InvestorsObserver

SAGE Therapeutics Inc (SAGE) is around the middle of the Biotechnology industry according to InvestorsObserver. SAGE received an overall rating of 40, which means that it scores higher than 40 percent of all stocks. SAGE Therapeutics Inc also achieved a score of 60 in the Biotechnology industry, putting it above 60 percent of Biotechnology stocks. Biotechnology is ranked 111 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

SAGE Therapeutics Inc (SAGE) stock is trading at $55.69 as of 11:47 AM on Thursday, Jun 17, an increase of $0.81, or 1.48% from the previous closing price of $54.88. The stock has traded between $53.80 and $56.36 so far today. Volume today is 872,840 compared to average volume of 911,752.

Click Here to get the full Stock Score Report on SAGE Therapeutics Inc (SAGE) Stock.

Read more:
Is SAGE Therapeutics Inc (SAGE) Stock at the Top of the Biotechnology Industry? - InvestorsObserver

Nano Biotechnology Market Projected to Show Strong Growth With Top 10 Key Players |Ablynx (Belgium), Nami Therapeutics (Us), Celgene Corporation (Us),…

The Nano Biotechnology Market statistical surveying report gives top to bottom information investigation by utilizing the different diagrams, figures, graphs, and tables. Besides, the report gives the diverse business challenges which are affecting business sector development in every which way. Global Nano Biotechnology Market report offers the organization profile of significant central participants including progress patterns, cutthroat scene breakdown, and key districts improvement status.

The Nano Biotechnology industry report lists the leading competitors and provides insights into strategic industry Analysis of the key factors influencing the market. The report includes the forecasts, Analysis, and discussion of important industry trends, market size, market share estimates, and profiles of the leading industry Players. The global Nano Biotechnology market is segregated by region under six major regions, namely North America, Asia-Pacific, Europe, China, the U.K., and the Rest-of-the-World.

Major industry Players:

GET SAMPLE COPY of this report @ https://www.infinitybusinessinsights.com/request_sample.php?id=564566

The Nano Biotechnology Market business inquiry recalls possible figures for the economy, creation, application facts, value trends. The market analysis divides the market by application type and topography in terms of interest and prices. According to the summary, the global Nano Biotechnology market is expected to reach XX$ 2021-2027 by 2020, with a CAGR of XX%.

Nano Biotechnology industry -By Application:

Nano Biotechnology industry By Product:

This Nano Biotechnology analysis provides the most recent Nano Biotechnology industry statistics, taking into account the various effects of COVID-19-related sector disruptions and halts. The new COVID-19 pandemic is having a major impact on the overall international exchange and businesses of the Nano Biotechnology industry.

Inquiry Before Buying @ https://www.infinitybusinessinsights.com/enquiry_before_buying.php?id=564566

Contact Us:Amit JainSales Co-OrdinatorInternational: +1 518 300 3575Email: inquiry@infinitybusinessinsights.comWebsite: https://www.infinitybusinessinsights.comFacebook: https://facebook.com/Infinity-Business-Insights-352172809160429LinkedIn: https://www.linkedin.com/company/infinity-business-insights/Twitter: https://twitter.com/IBInsightsLLP

Read the original here:
Nano Biotechnology Market Projected to Show Strong Growth With Top 10 Key Players |Ablynx (Belgium), Nami Therapeutics (Us), Celgene Corporation (Us),...

This Medical School Has An Admission Rate Of Less Than 1%: Heres How To Get In – Forbes

Kaiser Permanente Bernard J. Tyson School of Medicine is one of the newer medical schools it matriculated its inaugural class of 50 students in 2020but it is already one of the most competitive programs in the United States. With nearly 10,500 applicants in 2020-21, the medical school acceptance rate hovers around 0.05%.

Medical school student preparing her applications

Moon Prep sat down with Dr. Lindia J. Willies-Jacobo, MD, the Senior Associate Dean for Admissions. This interview reveals what the new medical school is prioritizing in their applicants and how students can be competitive applicants with resumes full of meaningful experiences, even during a pandemic. The full interview can be viewed here.

Dr. Lindia Willies-Jacobo is the Senior Associate Dean for Admissions and Equity, Inclusion, and ... [+] Diversity; Professor at Kaiser Permanente Bernard J. Tyson School of Medicine

Kristen Moon: What are the advantages and disadvantages of attending a newer medical school like Kaiser Permanente Bernard J. Tyson School of Medicine?

Dr. Lindia J. Willies-Jacobo: It's something we talk with students about during recruitment. Students are extraordinarily risk-averse, making it more difficult to commit to a brand new med school. However, I would argue that being part of a new school allows students to be innovative at our school.

For example, one of the things we've said to our students is they get to provide us with a lot of feedback. As the inaugural class, they have a significant impact on the direction in which the school goes. It tends to be the class that leaves a legacy.

The other piece I point out to students is that when you are building something new, you can think out of the box. I think when one goes to a traditional school that's been around for 10 or 50 years, it's a lot harder to enact even simple changes. With a new medical school, I think of it as a blank canvas that students really get to paint on.

Moon: What was the motivation for offering free tuition for the first five enrolling classes?

Willies-Jacobo: At our school, we do have free tuition and fees for any student who enrolls with us from between 2020-24. Many new schools do something similar and have built into that some level of tuition remission.

When you look at the cost of medical school education, it's astronomical. By offering free tuition, it allows students from economically disadvantaged backgrounds the opportunity to consider coming to medical school.

It also allows the students the opportunities to select specialties that really align with their personal and professional values without thinking too much about how much they're going to be remunerated as physicians later on. The reality is there are loans to be paid off. Students who may want to pursue primary care may decide otherwise because then the remuneration for someone who does primary care is often quite a bit less than someone who does a surgical specialty or another specialty. This frees students up to make specialty decisions beyond thinking about loan payments.

Moon: In 2020-21, the medical school received more than 10,000 applicants, with an acceptance rate of 0.05%. What did you prioritize in your evaluation?

Willies-Jacobo: It's important to know and understand the mission of the school to which you're applying. When mentoring students or talking to pre-med students, I emphasize putting together a portfolio that demonstrates mission alignment.

I've had people say, Well, every application must look exactly the same, but it doesnt. We utilize a holistic approach, and what we are always looking at is whether the student's personal narrative coupled with the experiences they've listed on their application and supportive letters of recommendation fit together in ways that show us that they are mission-aligned.

We designed our secondary or school-specific application and interview process in a way that allows students to demonstrate if their professional and personal goals are aligned with those of the school.

Moon: Another interesting statistic is that 30% or more of your students are non-science majors. How can these non-science majors stand out?

Willies-Jacobo: Unlike when I went to med school when it seemed like everyone was a science major, we now know that depending on the school, you can have upward of 30-40% of non-science majors in your applicant pool. Each year, we see more and more of these types of students applying for medical school.

When we are assessing applicants for readiness for medical school, there are still prerequisites and recommended courses that every student has to take. We want to ensure that students who are non-same majors can also demonstrate readiness from a science perspective. Many non-science students are still academically strong, but they also bring so much value to the institution. Many non-science majors often see things very holistically and with an entirely different set of lenses.

Moon: Can you tell me about your interview process?

Willies-Jacobo: We use the hybrid model because we know that some students tend to thrive in one-on-one interviews, and others may do better in the Multiple Mini Interview (MMI). The hybrid method allows us to attract a diverse pool of students.

This past cycle, we did something very similar but pivoted to a virtual platform. To do so, we cut back on the number of MMI stations because we knew that Zoom fatigue is real. With the hybrid approach, we often will compare how they performed in the MMI versus the traditional interview.

We do find that extroverted students tend to do a lot better in MMI stations. You have to be a self-starter in terms of conversation, and we find that more extroverted students tend to warm up more quickly than introverted students who require a little bit more time.

Moon: How would you recommend students prepare for the hybrid interview?

Willies-Jacobo: Im a huge believer in practice. Of course, some people suggest that you cant practice, but I disagree with that.

I typically encourage students to meet with a mentor and review practice MMI stations or questions to have them practice responding to them. In a virtual space, it is a little harder to answer interview questions because youre not getting as many cues as you would in person.

I remind students that anything that they put in their application is fair game, so remember what you listed. For example, review your research experience, community-based experiences, extracurriculars because inevitably it's going to come on their interviews. There's nothing worse than applying in June, getting interviewed in November and having not a clue what you wrote down.

Moon: How many students do you interview each year and accept?

Willies-Jacobo: We interviewed a little over 700 candidates for about 50 spots. Typically it ends up being about a two-to-one ratio in terms of acceptance versus who ends up matriculating, which is about average for a school of our size.

Moon: How important is it to apply early in the cycle?

Willies-Jacobo: Please apply early. This past year, 60,000 candidates applied to med school, and in any given year, about 60% of students don't get into med school.

If you apply in September or October, it takes four to six weeks for the Association of American Medical Colleges (AAMC) to verify the files. Even though youre a phenomenal candidate, you might not get an interview because school runs out of interview spots.

Moon: How has Covid-19 affected the admission process for students?

Willies-Jacobo: On the national level, there was an 18% increase in applications. Personally, we had an 11% increase in our applications. But another thing that we saw was to make adjustments for the number of experiences that students list on their applications. Students had Fulbright Scholarships canceled. Students had research or volunteer experiences go virtual or canceled altogether. In-person shadowing was also completely off the table.

We did see an increase in students working as Covid-19 contact tracers or virtual medical scribes. Although they couldnt go into hospitals, they still found virtual experiences. We had a lot of students being innovative and really rose to the occasion and made do with what was a very, very challenging admissions cycle.

Moon: What type of services do you provide students to help them succeed?

Willies-Jacobo: Support comes from our Office of Student Affairs. Wellness is a core value, so we have the wellness program coordinator. We also have a clinical psychologist on-site, and one of the things we've tried to do at the school is to normalize mental health. We've encouraged every student to check in with our clinical psychologists at least two to three times in the first year.

We also have pretty robust academic support for the student. We have someone who works with them on study skills and strategies. I also want to highlight our coaching program; every student is paired with a physician coach. Students meet several times a year with their coaching groups. This is a pretty distinctive and forward-thinking aspect of our program.

Students can learn more about Kaiser Permanente Bernard J. Tyson School of Medicine and submit their application through the American Medical College Application System (AMCAS).

More:
This Medical School Has An Admission Rate Of Less Than 1%: Heres How To Get In - Forbes

Emory Apologizes to Medical School Applicant Rejected Because He Was Black – The New York Times

More than six decades after Marion Hood was rejected by Emory Universitys School of Medicine, he received another letter from the school. This time, it was an apology for refusing to admit him into its medical program because he was Black.

Your rejection letter serves as a somber reminder that generations of talented young men and women were denied educational opportunities because of their race, and our society was denied their full potential, said the letter, which was sent in March and signed by Vikas P. Sukhatme, dean of the Emory University School of Medicine. An apology does not undo our actions. It is an acknowledgment of the pain that was caused by our school, and an opportunity for us to share our regret directly with you.

As part of its Juneteenth programming, Emorys School of Medicine on Thursday apologized to Dr. Hood, now 83, at a virtual event for students, faculty and staff members.

In 1959, Marion Hood received a letter of rejection for no other reason than the fact that he was Black. To those who understand the history of our country that should not be a surprise, the universitys president, Gregory L. Fenves, said at the event. This one individual and this one letter vividly shows the systematic injustice of that time and the legacy Emory is still reckoning with.

Dr. Hood decided to pursue medicine when he was about seven or nine years old, after accompanying his mother, who was a nurse, to the doctor.

At the event on Thursday, he told the story of how they were ushered into the practice through the back door of the building and waited in a room that had no furniture, only Coca-Cola crates to sit on. They waited until the last person was seen, then the doctor saw Dr. Hoods mother.

I was fuming, Dr. Hood said. I said to myself that if I was a physician, my mother and my kind would not have to go in through the back door, or wait that long just to be seen.

Dr. Hood eventually went on to study medicine at Loyola University in Chicago and has had a long practice as a gynecologist and obstetrician in Atlanta.

He decided to apply to Emory after he graduated from Clark College, now known as Clark Atlanta University. During his graduation ceremony, Clark, a historically Black university, awarded an honorary degree to an Emory University professor.

Emory was yet to be desegregated, and wouldnt accept its first Black student until 1963.

I thought, he can come to my school and get an honorary degree and I cant put my foot on his campus, Dr. Hood said. I didnt think that was quite right.

He had already applied to Howard University and the Meharry School of Medicine in Nashville, and then decided to apply to Emory. A week later, on Aug. 5, 1959, he got a letter signed by the director of admissions at the time saying he was rejected.

I am sorry I must write you that we are not authorized to consider for admission a member of the Negro race, said the letter, The Atlanta Journal-Constitution reported. I regret that we cannot help you.

In determining how to apologize to Dr. Hood, Emory offered him an honorary degree. He told school officials he didnt need a degree anymore but the opportunity to tell his story to marginalized students appealed to him.

Dr. Hood said in an interview on Friday that it was important for people to know that, although he did get accepted to medical school eventually, he still faced discrimination.

He still has the rejection letter framed in his basement where only friends can see it.

He used to have it in his office, where he would use it as a reminder to new medical students about how far weve come, and how far we have to go, and how the cycle repeats itself.

Originally posted here:
Emory Apologizes to Medical School Applicant Rejected Because He Was Black - The New York Times

An Arizona student was arrested after threatening to kill medical school classmates and bomb the campus, authorities say – CNN

The student faces four felony counts of computer tampering by using a computer in a course of conduct that threatened, terrorized or tormented specific individuals, police said.

It's unclear if she has legal representation.

The dean of Midwestern University at Glendale contacted authorities in April and reported that the student had sent a message from their phone threatening to bomb the campus, according to police and a probable cause statement.

When the dean confronted the student, she denied sending the message, the probable cause statement says.

The dean said the student was not doing well in school and was set to take her third medical board test after failing the first two, adding that if she failed the last test, she would be removed from the school, according to the court documents.

Earlier this month, a mass email was sent to about 200 students that named victims the author wanted to kill, according to police and the probable cause statement.

"Several more emails were sent in group messages threatening death and involving the families of the students," police added.

The student was arrested Wednesday after she was linked to the email addresses, social media accounts and electronic devices that were involved in the threatening messages, police said. The FBI is assisting in the investigation.

The rest is here:
An Arizona student was arrested after threatening to kill medical school classmates and bomb the campus, authorities say - CNN

The Real Reason Why Its Harder Than Ever To Get Into Medical School And What Aspiring Physicians Can Do To Improve Their Chances – Forbes

Its common knowledge that getting into medical school is tough.

Now, its tougher than ever.

More than two dozen schools reported a 25 percent increase in applicants in late 2020 over the previous year, according to the Association of American Medical Colleges.

ADVERTISEMENT

Consider this: Normal year-over-year growth is about 3 percent, the AAMC said.

That trend has caused admission rates at 10 of the toughest schools to drop to 2.6 percent or less. The newly-formed Kaiser Permanente Bernard J. Tyson School of Medicine has an admissions rate of only 0.5 percent.

Those additional applicants are motivated, in part, by the Covid-19 pandemic and are part of what experts are calling The Fauci Effect. Its the notion that Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, and his leadership during the Covid-19 pandemic has driven interest in healthcare careers.

Aspiring doctors should take more care in building their medical school list, creating a strong ... [+] resume, and distinguishing themselves from other applicants in the competitive process.

Why Covid-19 Ignited Passions And Motivated More Applicants

The increase in medical school applicants has been spurred, in part, by those motivated by the Covid-19 pandemic, said Geoffrey Young, Ph.D., AAMC senior director for student affairs and programs. Young compared their motivation to pursue a medical career with the increased interest in joining the military shortly after 9/11.

Physicians are being hailed as heroes; students feel inspired and energized by this, said Moon Prep Counselor Lindsey Conger. Plus, because of quarantining, many students have more time on their hands and are applying to more schools.

Other factors in increased competitiveness include earlier pre-med schooling (STEM programs as early as elementary school) and higher GPAs and MCAT scores.

To deal with the influx of applications, some schools are enlisting the help of additional reviewers to comb through and select the best-fit candidates. Most schools have no plans to expand enrollment in any meaningful way, according to the AAMC. Meaning, competition truly is as steep as it appears.

Though the prospects of getting into medical school appear daunting, Conger has a few tips for applicants wanting to boost their chances.

More Applications, Passion Projects Can Up Your Chances of Getting Into Med School

ADVERTISEMENT

In a typical year, Conger recommends applicants apply to at least 20 to 25 schools.

Now, shes urging applicants to submit 30 applications or more. This is also true, regardless of the pandemics impact, for students with below-average MCAT scores or GPAs. The more applications sent, the more chances there are to get accepted, she said.

Another way to improve chances of being accepted into medical school is to apply to both DO (osteopathic) and MD (allopathic) medical schools. At the end of the day, you are becoming a doctor, even if the letters after your name are slightly different, said Conger. ...DO schools tend to be slightly less competitive, so they can be good options for students.

To surviveand thrive inthe increasingly competitive med school admissions landscape, students are also exploring more innovative ways to show their passion and stand out among the other applicants, said Conger.

ADVERTISEMENT

Students now have to take a few extra steps to stand out from the crowded field, and every aspect of the application matters, she said. Those extra steps often include pursuing a passion project. But with pandemic limitations in place over much of the past year, many in-person opportunities, especially in volunteer and clinical work, have been hard to come by.

Since many hospitals aren't accepting in-person volunteers, my students are having to work a bit harder than usual. However, opportunities are out there. My students have done volunteering online through platforms like Crisis Text Line or virtual medical scribing. Virtual physician shadowing has also become a popular alternative, said Conger.

Students have had to adapt and pursue virtual opportunities in lieu of real-world experience to help them get noticed in the application process.

ADVERTISEMENT

Slimmer Admissions Chances Mean Doubling-Down On Effort

In a world thats still reeling from and dealing with the widespread effects of the Covid-19 pandemic, medical school admissions have not gone untouched. Although the admissions landscape looks grimmer than usual for med school hopefuls, there are still ways to put in extra effort and stand apart from the crowd.

Increasing the number of applications and being resourceful in finding volunteer opportunities are two ways an applicant can increase the odds of making it into med school, including those with the lowest admission rates.

Moon Preps 10 Toughest Medical School Admission Rates for 2021

10. Perelman School of Medicine at the University of Pennsylvania

ADVERTISEMENT

9. Washington University in St. Louis School of Medicine

8. The Johns Hopkins University School of Medicine

ADVERTISEMENT

7. Columbia University Vagelos College of Physicians and Surgeons (tie)

ADVERTISEMENT

7. Yale School of Medicine (tie)

5. Vanderbilt University School of Medicine (tie)

ADVERTISEMENT

5. Duke University School of Medicine (tie)

3. University of Chicago Division of the Biological Sciences Pritzker School of Medicine

ADVERTISEMENT

2. New York University (Grossman)

1. Kaiser Permanente Bernard J. Tyson School of Medicine

ADVERTISEMENT

See the rest here:
The Real Reason Why Its Harder Than Ever To Get Into Medical School And What Aspiring Physicians Can Do To Improve Their Chances - Forbes

Serving those who served – Northwestern Now – Northwestern University NewsCenter

Russell, you completed a large chunk of your clinical training at Jesse Brown. How did that come to be?

After I had my first medical school rotation at the VA, I chose the VA for every other rotation I could. All of my interactions there were just so positive. I looked forward to coming back during my residency in ophthalmology.

What about the experience drew and kept you there?

The vets are just incredible and they all have such amazing stories. They've all lived through so much. It's people coming from different walks of life, and being there is a very enriching experience. You really feel like you're helping people who have, first of all, served and given so much to everybody in the United States, and also people who really need your help.

Russell Huang

What kind of population do you work with?

Jesse Brown is definitely an inner-city VA. The pathology is very advanced for a lot of these guys. These are people who are struggling with PTSD and other issues. They haven't been able to take care of themselves for years. So, you know, honestly there's nothing better than really just connecting with one of these vets. And, especially as a medical student, you have the ability to do so much. Every little thing that you do for them is so meaningful to them, and it really empowers you as a medical student.

How is the VA experience part of your residency program?

As ophthalmology residents at the VA, we spend at least six months there. Were in the clinic two to three days a week. And by our fourth year, we're in the operating room half the time.

What types of procedures are you doing?

There's a very high incidence of glaucoma and also very advanced cases of cataracts. Many patients walk into our office legally blind from their cataracts. Doing cataract surgery on them is one of the most satisfying surgeries that we do because we can restore their vision.

You must hear interesting stories.

Before COVID, we used to have this big waiting room full of guys, and you could hear them trading war stories, talking to each other about their eyes, talking to each other about everything else that's going on, and cracking jokes. I treated one guy who was working on a screenplay. Its fun.

How is your clinical training different because it is at the VA?

You learn to be very independent very hands-on. The VA really pushes you. You're the doctor, and the buck stops with you. If you think there's something a patient needs, you have to get it done and, for better or worse, thats what makes the VA such a special place.

Continue reading here:
Serving those who served - Northwestern Now - Northwestern University NewsCenter

Major Puzzle Piece To The Future Of Our City: New Medical School And Trauma Center To Be Built At Sleep Train Arena Site – CBS Sacramento

NATOMAS (CBS13) A medical schools battle to build is bringing new jobs to Sacramento.

City leaders just announced plans for Sleep Train Arena after seven years of sitting empty. California Northstate University will build a medical training facility. Its a plan that was rejected by another city just months ago.

The former home for the Sacramento Kings that was converted into a field hospital during the pandemic will be completely demolished, said CNU leaders. They will turn 35 acres into their newest campus, including a trauma center.

This was a puzzle piece, and a major puzzle piece, to the future of our city, said Sacramento Mayor Darrell Steinberg.

Sacramento City Councilmember Angelique Ashby said the project will create thousands of high-wage jobs and generate billions in economic output over the next ten years.

If theres a takeaway today, heres one of them: The Kings made good on their promise, this is exactly what they said they would do, she said.

California Northstate University initially tried to build this campus in Elk Grove, but city leaders there rejected the plan over concerns about traffic, noise and environmental impact. So the university pursued options in Rancho Cordova but eventually landed in Sacramento.

This is good for Elk Grove, too, and Rancho Cordova and Citrus Heights because Sacramento is the hub. This is the easiest spot to get to because we know that 16,000 people used to come here on any given night, Ashby said.

Theres been an ongoing community campaign to build a zoo at the Sleep Train Arena site. City leaders conducted a feasibility study but the effort never gained enough traction.

Dolores Santos husband worked at Sleep Train Arena when it first open. She says demolishing it will be a major memory lost.

We went to all of the Kings games and I thought it was a perfect place halfway between downtown and the airport, Santos said.

University officials say it will take about 3.5 years to build the first phase of the campus and they could get started by the end of this year.

See original here:
Major Puzzle Piece To The Future Of Our City: New Medical School And Trauma Center To Be Built At Sleep Train Arena Site - CBS Sacramento

Congratulations! | East Tennessee 19-year-old headed to medical school – WBIR.com

When Blake Ivey graduated high school at 17 years old, he already had his associate's degree from Roane State Community College.

KNOXVILLE, Tenn. When most people turned 19 years old, they were likely just starting college or entering the workforce. One East Knoxville teen is way ahead of that, already headed to medical school.

Blake Ivey started taking college courses while in high school. He graduated when he was 17 years old, and already had his associate's degree from Roane State Community College in hand. After high school, he transferred to the University of Tennessee.

He graduated from UT in May. Now, he is headed to Lincoln Memorial University to get started with medical school.

He accomplished all this after being born to a single mother in rural Campbell County. It was his dream ever since he was young to become a doctor, he said.

He said he started dreaming about being a doctor after seeing his grandfather pass away from a heart attack in 2010, while on a road trip with his family.

"That's the worst feeling you can ever have, is not being able to help somebody. And that's the inspiration for why I want to become a physician because I want to be the person who is able to solve that problem, being able to help those in need," he said.

He will start studying at LMU in July. He'll go there 4 years, and then will need at least 3 years of training before he can officially become a doctor. He said he hopes to become a family physician, but also said he is keeping his options open.

"First and foremost, you need to be able to believe in yourself," he said. "Another thing is, anything is possible. You need to have confidence in yourself, you need to have that hard work ethic and be able to get a support system."

See more here:
Congratulations! | East Tennessee 19-year-old headed to medical school - WBIR.com

Anthem Funds Initiative to Address Nevada’s Physician Shortage, Support Nevada’s Diverse Pre-Med Students and Promote Health Equity – Business Wire

RENO, Nev.--(BUSINESS WIRE)--Anthem Blue Cross and Blue Shield Nevadas Medicaid health plan has committed $75,000 to fund a new University of Nevada, Reno School of Medicine (UNR Med) initiative called See It To Be It. This initiative will connect aspiring physicians from populations that are underrepresented in medicine and from medically underserved communities with medical students and physicians from similar backgrounds. By supporting pre-med students as they navigate the medical school admissions process, the program will support UNR Med and Anthems shared commitment to preparing a diverse workforce of physicians. In turn, a more diverse medical workforce will be positioned to deliver more equitable healthcare services to multicultural, multiracial and socioeconomically diverse populations as well as to medically underserved communities.

Physician shortages are at an all-time high across the United States and have reached unprecedented levels in Nevada, especially in communities of underserved areas, said UNR Med Dean Thomas L. Schwenk, M.D. The See It To Be It initiative is intended to have a direct impact on developing a pipeline of physicians who have the cultural competency to build strong doctor-patient relationships and influence positive change in diverse communities. We believe this initiative will build a solid foundation for the future of our state, and we cannot thank Anthem enough for making the program possible.

According to a report from the Association of American Medical Colleges, the United States could see an estimated physician shortage of up to 139,000 physicians by 2033. Nevadas physician shortage is one of the most severe in the nation, with the state ranking 48th for physician-to-patient ratios. Nevada is also the fourth fastest growing state in the U.S., with Black and Latinx populations leading that growth. However, the number of practicing physicians in Nevada is not occurring at the same pace as the population growth, which will likely cause more access to care challenges, especially in fast-growing communities of color, in rural Nevada and among Nevadas tribal communities.

Several studies have demonstrated that patients from diverse backgrounds are more likely to form trusting bonds with and benefit from having doctors who come from their own communities and can identify with their stories and experiences, said Lisa Thompson, M.D., Anthem Blue Cross and Blue Shield Nevada Medicaid medical director and Health Equity Task Force leader. Anthem has made a commitment to identifying Nevada-specific health disparities, so we can introduce solutions that create more equitable healthcare experiences, enhance healthcare accessibility and improve health outcomes. Anthems collaboration with UNR Med on the See It To Be It initiative is just one example of how we are delivering on our commitment and living our mission to improve lives.

The See It To Be It initiative includes four elements:

Anthem recognizes the complexity of health and is committed to developing unique solutions that address the needs of the communities we serve, said Lisa Bogard, president, Anthem Blue Cross and Blue Shield Nevada, Medicaid. By offering innovative solutions and addressing barriers, we can make healthcare simpler, more accessible, more equitable and help improve the health of our state.

The See It To Be It initiative is expected to launch at the start of the 2021/2022 academic year. UNR Med has already hosted its first statewide meeting and invites physicians, community members and anyone interested in developing a diverse medical workforce, to become members of the See It To Be It community. UNR Med Outreach and Recruitment Coordinator, Andre Lawson and UNR Med Director of Admissions, Tamara Martinez-Anderson, will manage the initiative with support from a second-year medical student intern, Abel Edossa, and involvement by UNR Med Student Interest Groups. For more information, contact UNR Med at officeofadmissions@med.unr.edu.

About Anthem Blue Cross and Blue Shield Nevada

Anthem Blue Cross and Blue Shield Nevada helps improve healthcare access and quality for more than 600,000 Nevadans by developing innovative care management programs and services. Anthems top priority is the health and well-being of its members and enabling access to comprehensive healthcare. Through health education and community outreach programs, members are empowered to choose and sustain a healthy lifestyle. Anthem Blue Cross and Blue Shield is the trade name of Community Care health Plan of Nevada, Inc., an independent licensee of the Blue Cross and Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. To learn more, visit http://www.anthem.com. Also, follow us on Twitter at http://www.twitter.com/anthemBCBS_news or on Facebook at https://www.facebook.com/AnthemMedicaid/.

About University of Nevada, Reno School of Medicine

The University of Nevada, Reno School of Medicine, Nevadas first public medical school, is a community-based, research-intensive medical school with a statewide vision for a healthy Nevada. Since 1969, UNR Med has trained more than 3,900 students, residents and fellows. UNR Med continues to improve the health and well-being of all Nevadans and their communities through excellence in student education, postgraduate training and clinical care, research with local, national and global impact and a culture of diversity and inclusion. For more information, visit med.unr.edu.

The rest is here:
Anthem Funds Initiative to Address Nevada's Physician Shortage, Support Nevada's Diverse Pre-Med Students and Promote Health Equity - Business Wire